| BioWorld
WEBOct 22, 2003 — BioWorld MedTech. Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation, business, financing, regulation, science, product …
Getinge to acquire Paragonix for $477M | BioWorld
WEBAug 23, 2024 — Getinge AB agreed to acquire Paragonix Technologies Inc. for $477 million, including upfront and earn out payments. The deal marks Getinge’s entry into the global organ preservation and transportation market, a rapidly advancing field driven by rising transplant volumes, technological innovations and evolving clinical practices.
Licensing or Acquisition? Big Pharma Shares How They (and
WEBFeb 8, 2012 — Perhaps most interesting, both Greg Wiederrecht, vice president and head of external scientific affairs at Merck & Co. Inc., and George Golumbeski, senior vice president of business development at Celgene Corp., said they usually leave it up to the biotech to decide whether they’d prefer a licensing deal or an acquisition.
Stem cells eat dead cells to ensure tissue integrity | BioWorld
WEBAug 27, 2024 — Phagocytosis – eliminating millions of dead cells every day – requires specialized cells such as macrophages, the true professionals, which migrate to engulf waste and dying cells. But they are not the only ones that can perform this task, as scientists at Howard Hughes Medical Institute (HHMI) discovered when they investigated hair follicle stem cells (HFSCs), a tissue in constant ...
A Bridgebio not far: PDUFA looms for acoramidis, firm keeps busy
WEBAug 23, 2024 — As Bridgebio Pharma Inc. awaits word from the U.S. FDA regarding the small-molecule transthyretin (TTR) stabilizer acoramidis for TTR-mediated amyloidosis cardiomyopathy, the firm closely followed this week’s headline about another spinout with news that the Palo Alto, Calif.-based company has signed a joint research pact with Hitgen Ltd., of Chengdu, China.
Icecure's Prosense destroys 100% of breast cancer tumors
WEBAug 16, 2024 — Icecure Medical Ltd.’s Prosense system demonstrated a 100% success rate in destroying breast cancer tumors that were less than or equal to 25 millimeters, according to a study published in the British Journal of Radiology. Highfield Biopharmaceuticals Inc. has filed an IND application with China’s National Medical Products Administration ...
AI presents potential for new theories of medical product liability
WEBAug 26, 2024 — Product liability is always a point of concern for manufacturers of medical devices and other U.S. FDA-regulated products, and the broad contours of product liability jurisprudence are well known by corporate counsel. However, artificial intelligence products are rapidly pressing their way into routine clinical use, representing a technological shift that may occasionally deviate from the ...
Vutrisiran phase III boosts Alnylam; biopharma index outperforms
WEBAug 20, 2024 — The BioWorld Biopharmaceutical Index climbed 16.31% by the end of July, continuing its lead over both the Nasdaq Biotechnology Index, which rose 10.82%, and the Dow Jones Industrial Average, up 8.37%. This follows an 8.15% gain in the BBI at the close of May, marking a strong performance throughout 2024.
Mutated tumor suppressors may become oncogenes, potential
WEBAug 23, 2024 — Mutated tumor suppressors may become oncogenes, potential drug targets. A new study has shown that when a gene is mutated and its copy number is altered, the risk of that gene contributing to the development of cancer increases. Although it was already known that both variations together promoted cancer, …
New antirhinoviral compound with broad-spectrum activity …
WEBAug 20, 2024 — New antirhinoviral compound with broad-spectrum activity described. Aug. 20, 2024. Human rhinoviruses (hRVs) are associated with upper respiratory tract infections such as the common cold, otitis media or sinusitis. In immunocompromised individuals or older people, hRVs can exacerbate existing pulmonary conditions such as asthma or …
Skip to content